SR9009 (Stenabolic): Scientific Profile
Publicado el · Actualizado el
REV-ERBα/β agonist for metabolic research. It modulates circadian rhythms, promotes mitochondrial biogenesis, and optimizes fatty acid oxidation in experimental models.
SR9009, known in the experimental field as Stenabolic, is a synthetic ligand designed for the activation of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors play a critical role in the regulation of the cellular circadian clock network, influencing the expression of genes involved in glucose metabolism, lipid storage, and mitochondrial turnover. Research in animal models suggests that its administration can induce a more efficient metabolic phenotype, characterized by an increase in systemic oxygen consumption.
In laboratory settings, this compound has demonstrated the ability to alter muscle architecture through the stimulation of mitochondrial biogenesis and the degradation of dysfunctional mitochondria (mitophagy). These processes translate into a substantial improvement in the oxidative capacity of skeletal tissue, which has positioned SR9009 as a fundamental tool in the study of physical endurance and energy efficiency without the need for external mechanical stimuli.
Additionally, scientific research has focused on its impact on the lipid profile and systemic inflammation. SR9009 has been shown to reduce the synthesis of cholesterol and triglycerides in the liver, while modulating the immune response of macrophages. Its application in research is strictly limited to the analysis of metabolic pathways and circadian rhythm disorders, lacking approval for administration in human subjects in conventional clinical settings.
Mechanism of action
SR9009 acts as a high-affinity agonist for the REV-ERB receptors. Upon binding to these nuclear receptors, it enhances their function as repressors of gene transcription. This results in the suppression of genes involved in hepatic lipogenesis and gluconeogenesis, while simultaneously activating genes related to glucose transport and fatty acid oxidation in skeletal muscle, increasing mitochondrial density through the PGC-1α pathway.
Mechanism summary
A selective agonist of the REV-ERB receptors that synchronizes energy metabolism with circadian rhythms and promotes mitochondrial biogenesis.
Clinical Studies (7)
- SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. (Dierickx P, et al. · Proc Natl Acad Sci U S A · 2019) PMID 31127047.
- SR9009 improves heart function after pressure overload independent of cardiac REV-ERB. (Li H, et al. · Front Cardiovasc Med · 2022) PMID 35911512.
- Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists. (Li L, et al. · Bioorg Med Chem · 2024) PMID 39059249.
- Time-dependent effect of REV-ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice. (Ni Y, et al. · Chronobiol Int · 2023) PMID 37161366.
- In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011. (Geldof L, et al. · Int J Mol Sci · 2016) PMID 27706103.
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists (Solt, et al. · Nature · 2012) PMID 22460951.
- SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy (Shen, et al. · Theranostics · 2020) PMID 32292508.
Warnings
SR9009 (Stenabolic) is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Product exclusively for use in laboratory research
- Its short half-life requires specific administration protocols
- Solubility must be verified before assay preparation
- Models with preexisting renal or hepatic insufficiency
- Studies requiring absolute stability of the circadian cycle
- Interaction with other nuclear receptor ligands
Technical data
- CAS
- 1379686-30-2
- Molecular formula
- C20H24ClN3O4S
- Molecular weight
- 437.94 Da
- Compound type
- sarm
- Storage
- 15-30°C in a cool, dry place
- Shelf life (lyophilized)
- 24 months
- Shelf life (reconstituted)
- Not applicable (if tablet/powder)
- Light-sensitive
- No
Available for research
SR9009 (Stenabolic) is available as a research reagent (RUO):
Frequently asked questions about SR9009 (Stenabolic)
What is SR9009 (Stenabolic)?
REV-ERBα/β agonist for metabolic research. It modulates circadian rhythms, promotes mitochondrial biogenesis, and optimizes fatty acid oxidation in experimental models.
What is the mechanism of action of SR9009 (Stenabolic)?
A selective agonist of the REV-ERB receptors that synchronizes energy metabolism with circadian rhythms and promotes mitochondrial biogenesis.
What is SR9009 (Stenabolic) researched for?
In preclinical research, SR9009 (Stenabolic) is studied mainly in: Modulation of mitochondrial biogenesis in muscle tissue; Research on the optimization of fatty acid oxidation; Study of the regulation of metabolic circadian rhythms. Material exclusively for scientific research.
What are the chemical properties of SR9009 (Stenabolic)?
Molecular formula C20H24ClN3O4S; molecular weight 437.94 Da; CAS number 1379686-30-2.
How is SR9009 (Stenabolic) stored?
Storage conditions: 15-30°C in a cool, dry place; lyophilized stability: 24 months; once reconstituted: Not applicable (if tablet/powder).
What routes of administration are studied for SR9009 (Stenabolic)?
In research models the following are described: Oral (Research), Subcutaneous. Use is exclusively for scientific research.